Abstract
Objective To study the effect of prednisone combined with vitamin D in the treatment of primary nephrotic syndrome in children. Method 73 cases of primary nephrotic syndrome admitted to the nephrology department of our hospital were randomly selected and retrospectively analyzed. 36 cases were treated with prednisone as the control group, and 37 cases were treated with prednisone combined with vitamin D as the observation group. The efficacy was compared after 3 months of continuous treatment. Result After 3 months of treatment, the blood calcium of the observation group was higher than that of the control group, PTH was lower than that of the control group, and 25-(OH)2D3 and 1,25-(OH)2D3 were higher than those of the control group (P < 0.05). After 1, 2, and 3 months of treatment in the observation group, Scr and 24-h urine protein quantification were lower than those in the control group and eGFR was higher than that in the control group (P < 0.05). CD4+ and CD4+/CD8+ were lower in the observation group than in the control group after 3 months of treatment (P < 0.05). The serum sTfR and TGF-β1 levels were lower in the observation group than in the control group after 3 months of treatment (P < 0.05). The total effective rate of the observation group was 83.78% after 3 months of combined treatment with prednisone and vitamin D, which was significantly higher than the total effective rate of the control group of 61.11% (P < 0.05). The incidence of nausea and vomiting, heartburn, headache, dry cough, hypercalcemia, and constipation during treatment in the observation group was not statistically different from that in the control group (P > 0.05). Conclusion Combined treatment of primary nephrotic syndrome in children with prednisone and vitamin D can more significantly improve the level of clinical indicators, improve renal function and immune function, and obtain more satisfactory efficacy, without significantly affecting the safety of treatment.
Highlights
Primary nephrotic syndrome is a group of nephropathies with a high incidence in the pediatric stage, mostly occurring in the glomerulus, and is a common manifestation of pediatric chronic kidney disease in which children are clinically hyperlipidemic and hypoalbuminemic, with massive proteinuria and varying degrees of edema [1]
Glucocorticoids have been the drug of choice for treating primary nephrotic syndrome and have been used in clinical treatment for a long time. e practice has shown that most pediatric primary nephrotic syndrome has a high sensitivity to glucocorticoid therapy and can achieve a satisfactory prognosis through treatment
1,25-(OH)2D3 were higher in the observation group than in the control group (P < 0.05); after 3 months of treatment, there was no significant difference in blood phosphorus between the observation group and the group before treatment (P > 0.05), blood calcium was higher than before treatment, parathyroid hormone (PTH) was lower than before treatment, and 25-(OH)2D3 and 1,25-(OH)2D3 were higher than before treatment (P < 0.05); after 3 months of treatment in the control group, blood phosphorus, blood calcium, and PTH were not statistically different from those before treatment (P > 0.05) and 25-(OH)2D3 and 1,25-(OH)2D3 were higher than before treatment (P > 0.05) (Figure 1)
Summary
To study the effect of prednisone combined with vitamin D in the treatment of primary nephrotic syndrome in children. E serum sTfR and TGF-β1 levels were lower in the observation group than in the control group after 3 months of treatment (P < 0.05). E total effective rate of the observation group was 83.78% after 3 months of combined treatment with prednisone and vitamin D, which was significantly higher than the total effective rate of the control group of 61.11% (P < 0.05). Combined treatment of primary nephrotic syndrome in children with prednisone and vitamin D can more significantly improve the level of clinical indicators, improve renal function and immune function, and obtain more satisfactory efficacy, without significantly affecting the safety of treatment
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
